Diligence memo · auto-generated · as of July 2, 2026
Synedgen, Inc.
Synedgen, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Synedgen, Inc. operates in Pharmaceuticals, based in CLAREMONT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Synedgen, Inc. has raised $24M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.0M on 2016-04-13.
Most recent recorded round closed around 2024-09-11.
Valuation (modeled)modeled
Provath models Synedgen, Inc. at approximately $8.3M (range $2.0M–$17M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.25× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 22 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 69% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 14% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.